“It is a pleasure to welcome Max and Glenn to the team at this critical juncture for Aurinia. As we continue to build and expand the organization and prepare for the potential U.S. commercialization of voclosporin, their respective talents complement …
Latest News From Lumira Ventures
Celgene Exercises Commercial Option for Zymeworks’ Azymetric™ Platform Triggering $7.5MM Milestone Payment
VANCOUVER, British Columbia–(BUSINESS WIRE) — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that its global biopharma partner Celgene Corporation has selected a lead therapeutic candidate in oncology for further development and exercised its option …
Endotronix Enrolls First Patient in SIRONA II CE Mark Trial
Study to support European clearance of Cordella™ Pulmonary Artery Sensor System for treatment of patients with chronic heart failure LISLE, IL – Endotronix Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced …
Opsens Releases Promising Q3 2019 Financials
QUEBEC CITY, July 11, 2019 /CNW Telbec/ – Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) today reported its results for the third quarter of 2019. HIGHLIGHTS Consolidated revenues of $7.9 M for the third quarter of 2019 compared with $6.4 M for the third quarter of 2018, an increase …
Epilepsia Publishes Phase 2a Data for Staccato Alprazolam
– Staccato alprazolam is shown to rapidly suppress seizure activity at two minutes in five patients with epilepsy – – Staccato alprazolam generally well tolerated; no serious or severe adverse events reported – – Enrollment in Phase 2b, double-blind, placebo-controlled …
Exact Imaging Receives Frost & Sullivan’s 2019 Imaging Technology Innovation Award
TORONTO, CANADA — Exact Imaging, the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, is the proud recipient of Frost & Sullivan’s 2019 Global Prostate Cancer Diagnostic Imaging Technology Innovation Award. “Exact Imaging’s …
Shareholders Overwhelmingly Support Aurinia & Its Board of Directors
Dissident Withdraws the Consents of its Nominees from Consideration Prior to the AGM Aurinia Reaffirms its Commitment to Voclosporin and Creating Shareholder Value VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) is pleased to …
Pharmaceutical Industry Executive, Adele M. Gulfo Joins Medexus Pharmaceuticals’ Board of Directors
MONTREAL, June 25, 2019 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), a leading specialty pharmaceutical company with a strong North American commercial platform, announces that Adele M. Gulfo has joined the Company’s Board of Directors, …
Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study
TORONTO, June 20, 2019 /CNW/ — Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, reported today that the U.S. Food and Drug Administration has notified the company that it may proceed with its clinical investigation of EB01, a novel sPLA2 inhibitor, which …
Bardy Diagnostics™ Selected as 1 of 50 Leading Startups in the 2019 MedTech Innovator Showcase Program
SEATTLE, June 19, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that MedTech Innovator, the premier nonprofit startup accelerator in the medical technology industry, has selected BardyDx to participate in the …
Zymeworks Announces Pricing of $175 million Public Offering
VANCOUVER, British Columbia — Zymeworks Inc. (NYSE/TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics (the “Company”), announced today the pricing of its previously announced underwritten public offering (the “Offering”) of 5,555,556 common shares and, to a certain investor, pre-funded warrants …
Phase 2 Trial Data Demonstrates Longer Survival Rates for Women with Metastatic Breast Cancer Receiving Trilaciclib & Chemotherapy
– Detailed data from this trial will be presented at a medical meeting later this year – RESEARCH TRIANGLE PARK, N.C., June 18, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from …
G1 Therapeutics Appoints Garry Nicholson to Chair of the Board of Directors
– Garry Nicholson to serve as new board chair –– Sir Andrew Witty, Fredric Eshelman, Pharm.D. and prior chair Seth Rudnick, M.D. re-elected – RESEARCH TRIANGLE PARK, N.C., June 13, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a …
Bardy Diagnostics™ Selected as Winner of the MedTech Breakthrough Award For Best New Diagnostic Technology
SEATTLE, June 6, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that MedTech Breakthrough, an independent organization that recognizes the top companies and solutions in the global health …
Bellingham Urology Group Acquires First ExactVu™ System in Washington State
TORONTO, CANADA — (June 4, 2019) Exact Imaging, the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announced that Bellingham Urology Group has acquired the ExactVu™ micro-ultrasound system for real-time targeted prostate biopsies. …